Last reviewed: June 6, 2026
Last updated: June 6, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, the active ingredient in Ozempic and Wegovy, activates GLP-1 receptors in the brain to decrease hunger signals and slow stomach emptying. Originally approved for diabetes management, semaglutide has become one of the most studied medications for weight loss, with clinical trials showing average weight reductions of 15–22% over 68 weeks. PlexusDx provides access to compounded semaglutide injections through licensed 503A pharmacies, serving all 50 states without insurance requirements or membership fees.
How Semaglutide Works for Weight Loss
Semaglutide belongs to a class of medications called GLP-1 receptor agonists. When you inject semaglutide, it mimics glucagon-like peptide-1, a natural hormone that controls appetite and blood sugar. The medication signals your brain's appetite centers to reduce hunger, increases feelings of fullness, and slows how quickly food moves through your stomach. This combination of effects leads to reduced calorie intake without requiring extreme dietary restriction.
Research from the STEP trials demonstrated that semaglutide users lost an average of 15 pounds per month during the first three months of treatment, with sustained weight loss continuing over one year. The medication also improves metabolic markers including fasting glucose, insulin levels, and inflammation. Unlike older weight loss drugs that stimulate metabolism or increase energy, semaglutide works by fundamentally changing how your body regulates hunger and satiety signals.
Semaglutide vs. Ozempic: What's the Difference?
Ozempic is a brand-name injectable semaglutide manufactured by Novo Nordisk and originally approved by the FDA for type 2 diabetes management. Wegovy is the same semaglutide molecule approved specifically for weight loss, also made by Novo Nordisk. Both contain identical active ingredients but differ in approval indication, pre-filled pen design, and cost. Brand semaglutide typically costs $900–$1,300 per month through retail pharmacies.
PlexusDx compounds semaglutide from licensed 503A compounding pharmacies, making it available at a starting price of $149 per month regardless of your dose level. Compounded medications contain the same pharmaceutical-grade active ingredient as brands but are prepared by licensed pharmacists in accredited facilities. PlexusDx serves all 50 states, accepts HSA and FSA funds, and requires no insurance or membership fees, making semaglutide accessible to patients who otherwise cannot afford brand options.
Clinical Evidence for Semaglutide Weight Loss Effectiveness
The STEP program included four randomized controlled trials involving over 4,500 adults with obesity or overweight with weight-related conditions. Participants receiving semaglutide 2.4 mg weekly lost an average of 35 pounds over 68 weeks, compared to 6 pounds in the placebo group. Weight loss benefits persisted beyond the trial period in follow-up studies, with many patients maintaining 80% of their achieved weight loss one year after completing treatment. Cardiovascular outcomes also improved, including reduced blood pressure, triglycerides, and inflammatory markers.
Semaglutide also reduces the risk of major cardiovascular events in people with type 2 diabetes and obesity, according to the SUSTAIN-6 trial. Beyond weight loss, the medication improves insulin sensitivity, reduces liver fat content, and may slow the progression of kidney disease in diabetic patients. These metabolic benefits suggest semaglutide addresses underlying dysfunction in appetite regulation and glucose control rather than simply suppressing appetite as an isolated effect.
Understanding Side Effects and Safety Considerations
The most common side effects of semaglutide include nausea, vomiting, diarrhea, and constipation, particularly during dose escalation phases. These gastrointestinal effects typically emerge in the first 2–4 weeks and often improve as your body adjusts. Serious but rare side effects include pancreatitis, gallbladder problems, and changes in vision. You should not use semaglutide if you have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.
PlexusDx patients receive medications prepared under sterile conditions by licensed pharmacists and should work with a healthcare provider to monitor blood sugar, kidney function, and for symptoms of pancreatitis. The dose escalation schedule—typically starting at 0.25 mg weekly and increasing by 0.25 mg every four weeks—allows your body to adapt gradually and minimize side effects. Because semaglutide is not FDA-approved in its compounded form, patients should understand they are using a compounded medication prepared from pharmaceutical-grade ingredients in a regulated 503A facility.
Personalized Treatment with Genetic Testing
Not everyone responds identically to semaglutide, and genetic variations influence how effectively the medication works for you. PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after your first month) to map 14 different appetite-regulation pathways, 49 individual peptides, and 150+ genetic insights. Key variants such as GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 affect how your body produces and responds to appetite-suppressing hormones.
Understanding your genetic peptide profile helps PlexusDx providers predict which medication—semaglutide injection, oral semaglutide, tirzepatide, or combination compounds—will likely produce the best results for your individual biology. Patients with certain FTO variants may see enhanced weight loss with GLP-1 therapy, while those with specific GIPR variants might benefit from dual-compound approaches like GLP-Squared. This precision approach transforms weight loss from trial-and-error treatment to personalized medicine aligned with your genetic predispositions.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is semaglutide safe for long-term weight loss use?
Yes, clinical trials spanning up to one year demonstrate semaglutide safety and sustained weight loss. Most side effects are temporary and manageable through gradual dose escalation. However, semaglutide is not appropriate for people with a history of medullary thyroid cancer or multiple endocrine neoplasia, and it should be used under healthcare provider supervision with regular monitoring of kidney function and blood sugar.
How much weight can I expect to lose with semaglutide?
Clinical trial data shows average weight loss of 15–22% of body weight over 68 weeks on semaglutide 2.4 mg weekly. Individual results vary based on genetics, lifestyle, baseline weight, and medication response. PlexusDx's Precision Peptide Genetic Test can help predict your likely response by analyzing key appetite-regulation genes like GLP1R and FTO variants.
How much does PlexusDx compounded semaglutide cost?
PlexusDx compounded semaglutide injections start at $149 per month regardless of your dose level—your dose may increase, but your price won't. The medication is prepared by licensed 503A compounding pharmacies, serves all 50 states, requires no insurance, and is HSA/FSA eligible. An optional Precision Peptide Genetic Test costs $99 as an add-on after your first month.
What is the difference between compounded and brand semaglutide?
Compounded semaglutide contains the same pharmaceutical-grade active ingredient as Ozempic or Wegovy but is prepared by licensed pharmacists in 503A compounding facilities rather than manufactured by a pharmaceutical company. The clinical mechanism and effects are identical; the primary differences are cost, access, and regulatory pathway. Brand semaglutide typically costs 6–9 times more than PlexusDx compounded versions.
Can genetic testing predict if semaglutide will work for me?
PlexusDx's Precision Peptide Genetic Test analyzes 150+ genetic insights across 49 peptides to predict your response to GLP-1 medications like semaglutide. Variants in GLP1R, GIPR, FTO, and MC4R genes influence appetite regulation and weight loss potential. Testing provides personalized recommendations about which medication—semaglutide injection, oral semaglutide, tirzepatide, or combination compounds—will likely work best for your unique biology.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How to Maintain Weight Loss After GLP-1 Medications
Navigating the Differences Between Wegovy and Ozempic: A Comprehensive Guide to Side Effects and Selection